These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 29541892)
1. VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen. Truong H; Gomella LG; Thakur ML; Trabulsi EJ World J Urol; 2018 May; 36(5):719-726. PubMed ID: 29541892 [TBL] [Abstract][Full Text] [Related]
8. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. Zhang K; Aruva MR; Shanthly N; Cardi CA; Rattan S; Patel C; Kim C; McCue PA; Wickstrom E; Thakur ML J Nucl Med; 2008 Jan; 49(1):112-21. PubMed ID: 18077536 [TBL] [Abstract][Full Text] [Related]
9. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
10. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. Thakur ML; Aruva MR; Gariepy J; Acton P; Rattan S; Prasad S; Wickstrom E; Alavi A J Nucl Med; 2004 Aug; 45(8):1381-9. PubMed ID: 15299065 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628 [TBL] [Abstract][Full Text] [Related]
12. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244 [TBL] [Abstract][Full Text] [Related]
13. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
14. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Fernández-Martínez AB; Carmena MJ; Arenas MI; Bajo AM; Prieto JC; Sánchez-Chapado M Histol Histopathol; 2012 Aug; 27(8):1093-101. PubMed ID: 22763881 [TBL] [Abstract][Full Text] [Related]
17. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071 [TBL] [Abstract][Full Text] [Related]
18. Benign Prostatic Hyperplasia-Related False-Positive of Prostate-Specific Membrane Antigen-Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles' Heel of Biopsy-Free Radical Prostatectomy? Tang W; Tang Y; Qi L; Zhang Y; Tang G; Gao X; Hu S; Cai Y J Urol; 2023 Dec; 210(6):845-855. PubMed ID: 37647549 [TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives. Lin M; Ta RT; Kairemo K; Le DB; Ravizzini GC Cancer Biother Radiopharm; 2021 Apr; 36(3):237-251. PubMed ID: 32589458 [TBL] [Abstract][Full Text] [Related]
20. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]